Search

TG Therapeutics Inc

Geschlossen

BrancheGesundheitswesen

64.4 0.36

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

63.94

Max

64.62

Schlüsselkennzahlen

By Trading Economics

Einkommen

48M

55M

Verkäufe

20M

260M

KGV

Branchendurchschnitt

94.597

68.089

EPS

0.35

Gewinnspanne

21.337

Angestellte

399

EBITDA

64M

86M

Empfehlungen

By TipRanks

Empfehlungen

Buy

12-Monats-Prognose

+18.43% upside

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

525M

9.7B

Vorheriger Eröffnungskurs

64.04

Vorheriger Schlusskurs

64.4

TG Therapeutics Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

13. Nov. 2026, 21:13 UTC

TG Therapeutics, Inc. shares are modestly lower in after-market trading, reflecting broader market declines influenced by the Federal Reserve's financial stability report.

12. Nov. 2026, 23:06 UTC

TG Therapeutics, Inc. shares are modestly lower in after-market trading following fluctuations earlier in the session.

11. Nov. 2026, 23:06 UTC

TG Therapeutics, Inc. is trading slightly lower in after-market hours after peaking earlier.

10. Nov. 2026, 21:03 UTC

Social Media
News

TG Therapeutics stock advanced after Evercore ISI maintained its Outperform rating and J.P. Morgan raised its global revenue guidance to $1 billion.

9. Nov. 2026, 23:06 UTC

Social Media

TG Therapeutics, Inc. is trading slightly higher in after-market hours following the completion of a $100 million share repurchase program, buying back 3.5 million shares.

6. Nov. 2026, 22:51 UTC

TG Therapeutics, Inc. is trading modestly higher in after-market hours, reflecting broader market gains following strong U.S. labor market data for October.

5. Nov. 2026, 23:03 UTC

TG Therapeutics, Inc. shares advanced modestly during after-market hours on Thursday, fluctuating from negative territory to a high nearing 1%.

4. Nov. 2026, 23:26 UTC

TG Therapeutics, Inc. is roughly flat in after-market trading, slightly declining from an early high but remaining above its 20-day moving average.

3. Nov. 2026, 22:51 UTC

TG Therapeutics, Inc. is advancing in after-market trading, moving higher alongside the broader market following a recovery from an initial dip after Tuesday's close.

2. Nov. 2026, 23:51 UTC

TG Therapeutics, Inc. shares advanced in after-market trading, moving higher alongside the broader market, despite some volatility during the session.

31. Okt. 2026, 00:02 UTC

TG Therapeutics, Inc. is trading higher in after-market hours, reaching its highest cumulative return of the day and significantly surpassing Friday's close.

30. Okt. 2026, 23:31 UTC

TG Therapeutics, Inc. shares traded modestly higher during after-market hours on Friday, continuing a trend of higher daily closes since the prior close.

29. Okt. 2026, 22:26 UTC

TG Therapeutics, Inc. is experiencing a notable decline in after-market trading, retracing from earlier gains and marking a significant drop since Thursday's close.

28. Okt. 2026, 23:06 UTC

Social Media

TG Therapeutics, Inc. shares are trading lower in after-market hours ahead of earnings on Monday, fluctuating between a loss of over two percent and a slight gain.

27. Okt. 2026, 20:51 UTC

TG Therapeutics, Inc. is trading higher in after-market hours, recovering from earlier losses to reach a notable peak above its 20-day moving average.

26. Okt. 2026, 20:13 UTC

TG Therapeutics Inc shares are trading modestly lower in after-market hours, following three consecutive sessions of gains and an unusual lack of variation.

23. Okt. 2026, 20:03 UTC

Social Media
News

TG Therapeutics announced initial Phase 1 study results showing 89% of participants with progressive multiple sclerosis had stable or improved disability scores at Day 90.

22. Okt. 2026, 20:07 UTC

TG Therapeutics Inc shares fell slightly, retracing from an early peak and ending near the lower end of their one-month range.

21. Okt. 2026, 19:36 UTC

Social Media
News

TG Therapeutics presented new clinical data for BRIUMVI at the MSToronto2026 conference, showing 88% of patients free from disability progression after continuous treatment.

20. Okt. 2026, 22:36 UTC

Social Media

TG Therapeutics Inc is trading lower in after-market hours, having retraced from an earlier high and positioned near the lower end of its one-month trading range.

19. Okt. 2026, 20:07 UTC

Social Media

Shares of TG Therapeutics Inc are declining, finishing well below the 20-day moving average and near the lower end of the one-month range.

16. Okt. 2026, 19:53 UTC

Social Media

TG Therapeutics Inc shares are declining sharply, trading well below their 20-day moving average and near the lower end of their one-month range.

15. Okt. 2026, 20:07 UTC

TG Therapeutics Inc shares advanced, peaking in the late morning and settling near the day's high, remaining above its 20-day moving average.

14. Okt. 2026, 23:21 UTC

TG Therapeutics Inc shares declined in after-market trading, moving lower alongside the broader market amid significant declines in technology stocks and rising crude oil prices.

12. Okt. 2026, 19:56 UTC

Social Media
News

TG Therapeutics published a five-year study showing BRIUMVI has a lower risk of disability progression compared to ocrelizumab and ofatumumab in relapsing multiple sclerosis.

10. Okt. 2026, 00:01 UTC

TG Therapeutics Inc shares are trading modestly higher in after-market hours, continuing a trend of four consecutive sessions finishing higher.

9. Okt. 2026, 23:20 UTC

TG Therapeutics Inc shares are trading modestly lower in after-market hours, having fluctuated between a decline and a slight gain since Friday's close.

8. Okt. 2026, 19:15 UTC

News
Social Media
Event

TG Therapeutics schedules the 10th Joint ACTRIMS-ECTRIMS Meeting for October 21-23, 2026, to present initial clinical results of Azer-Cel and BRIUMVI data.

7. Okt. 2026, 20:01 UTC

TG Therapeutics Inc is trading higher, having previously peaked earlier in the session before pulling back, and remains below its 20-day moving average.

6. Okt. 2026, 20:00 UTC

TG Therapeutics Inc shares fell sharply, reaching an early high before declining significantly, remaining well below its 20-day moving average.

Peer-Vergleich

Kursveränderung

TG Therapeutics Inc Prognose

Kursziel

By TipRanks

18.43% Vorteil

12-Monats-Prognose

Durchschnitt 76.4 USD  18.43%

Hoch 86 USD

Tief 71 USD

Basierend auf 6 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für TG Therapeutics Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

6 ratings

5

Buy

0

Halten

1

Sell

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über TG Therapeutics Inc

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Umbralisib, an oral inhibitor of PI3K-delta inhibitor for the treatment of adult patients with relapsed or refractory marginal zone lymphoma and follicular lymphoma; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; and Novimmune SA, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. TG Therapeutics, Inc. was incorporated in 1993 and is based in Morrisville, North Carolina.
help-icon Live chat